Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma
Key facts
- Who runs it
- Louisiana State University Health Sciences Center in New Orleans
- Where
- New Orleans, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Jun 2021
- Ended
- 30 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Branch Chain Amino Acid
- maltodextrin
- Record updated
- 28 January 2022
- Why it stopped
- Dr. Marshall left UMC and LSU Health Sciences Center.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Have been diagnosed with HCC and deemed a candidate for nonsurgical local therapy (TACE and/or percutaneous ablation)
- Have a Child-Pugh score < 6
- Are at least 18 years of age or older
- Otherwise healthy adults
- Provide written consent to participate
Who cannot take part
- Are currently taking insulin or metformin
- Have a diagnosis of renal failure
- Have been diagnosed with branched-chain ketoaciduria (maple syrup urine disease)
- Have been diagnosed with a medical condition that warrants a low-protein diet
- Younger than 18 years of age
- Have a Child-Pugh score > 6
- Consume > 60g alcohol intake per day
- Have hepatic encephalopathy
- Pregnant women
- Are unable to provide consent
- Are incarcerated
Where in United States
- University Medical Center New OrleansNew Orleans, United States
About the trial
What the trial wants to find out
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer death among men. While several new treatment options have recently become available, they are costly and have a potential for significant, adverse side effects. Many patients diagnosed with HCC also suffer from underlying liver disease, including cirrhosis. As many as 80-90% of patients diagnosed with HCC also have cirrhosis. Protein-energy malnutrition (PEM) in cirrhosis is as high as 65-90% and significantly increases the risk of morbidity and mortality as well as decreased quality of life.
Read full original descriptionShow less
Branched-chain amino acid (BCAA) supplementation has been extensively studied for usefulness in liver disease, specifically to treat hepatic encephalopathy to and preserve and restore muscle mass. Maintenance of liver function and prevention of PEM are essential for improving outcomes in patients with HCC. Branched-chain amino acid supplementation in HCC has been studied extensively in China \& Japan with multiple studies showing improvements in liver function, progression-free survival, and overall survival. Additionally, patients in treatment groups have shown improvement in quality of life indicators. However, these results have yet to be replicated in the United States. Branched-chain amino acid supplementation may be a safe, low-cost approach to improve survival, liver function indicators, and quality of life for patients diagnosed with HCC.
In this study, patients with primary HCC will be randomized to either a treatment group, which will receive standard of care and BCAA supplement or to a control group which will receive standard of care and a maltodextrin placebo. Both groups will receive liver-directed therapy including transarterial chemoembolization (TACE) and thermal ablation. All patients will complete a quality of life survey (FACT-Hep) at each visit.
The 2 groups in the trial
- Control GroupPlacebo, for comparison
The control group will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic), consume a maltodextrin placebo supplement beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
Treatment: maltodextrin
- Intervention GroupTreatment being tested
In the intervention group, patients will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic) and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
Treatment: Branch Chain Amino Acid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Branched-chain Amino Acid Supplementation on Quality of Life and Overall Survival in Patients Receiving Liver Directed Therapy for Hepatocellular Carcinoma
- Record updated
- 28 January 2022